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SUMMARY
Transparency of the cornea is indispensable for optimal vision. Ocular trauma is a leading cause of corneal opacity, leading to 25 million
cases of blindness annually. Recently, mesenchymal stem cells (MSCs) have gained prominence due to their inflammation-suppressing
and tissue repair functions. Here, we investigate the potential of MSCs to restore corneal transparency following ocular injury. Using an
in vivo mouse model of ocular injury, we report that MSCs have the capacity to restore corneal transparency by secreting high levels of
hepatocyte growth factor (HGF). Interestingly, our data also show that HGF alone can restore corneal transparency, an observation that
has translational implications for the development of HGF-based therapy.
INTRODUCTION
A transparent cornea is crucial for optimal vision. Ocular
trauma, a leading cause of loss of corneal transparency, ac-
counts for approximately 25 million cases of blindness
annually (Resnikoff et al., 2008; Whitcher et al., 2001).
During ocular injury, inflammation-induced transforming
growth factor b (TGF-b), particularly TGF-b1 and TGF-b2,
drive the differentiation of corneal fibroblasts (activated
keratocytes) into a-smooth muscle actin (aSMA)-express-
ing myofibroblasts (Jester et al., 1997; Torricelli et al.,
2016), which are themselves opaque and produce disorga-
nized extracellular matrix, leading to the development of
corneal opacity and scarring (Jester, 2008; Jester et al.,
2012; Ljubimov and Saghizadeh, 2015). Recently, mesen-
chymal stem cells (MSCs) have been linked to a variety of
anti-inflammatory and repair functions in both ocular
and non-ocular tissue injuries (Basu et al., 2014; Jiang
et al., 2002; Lan et al., 2012; Lee et al., 2014; Uccelli et al.,
2008; Wang et al., 2011). However, ocular injuries
involving the cornea undergo a wound-healing process
that often results in scar formation and loss of corneal
transparency. Here, we report that bone marrow-derived
MSCs are capable of restoring corneal transparency after
injury involving corneal stroma. Specifically, we show
that MSCs secrete high levels of hepatocyte growth factor
(HGF), which inhibits the generation of opacity-inducing
myofibroblasts. Furthermore, we show that HGF alone
can restore corneal transparency in an in vivo model of
eye injury, a finding that offers an HGF-based therapeutic
approach that could potentially eliminate the need for
cell-based and conventional therapies.
RESULTS AND DISCUSSION
Inflammatory Milieu Drives MSCs to Secrete Elevated
Levels of HGF
The cornea is the most anterior tissue of the eye that com-
prises the epithelium, stroma, and endothelium (Nishida
and Saika, 2011). Ocular injuries involving the stroma (Fig-
ure 1A) lead to corneal scarring and compromised vision
(Jester, 2008; Whitcher et al., 2001). The aim of this study
was to determine whether MSCs have the potential to
restore corneal transparency following injury. To investi-
gate this, we first screenedMSCs for expression of potential
anti-inflammatory and growth factors under both homeo-
stasis and inflammatory conditions. In vitro expanded
and functionally characterized bone marrow-derived
MSCs (Figures 1B and 1C)were cultured in the absence (me-
dium alone) or presence of interleukin-1b (IL-1b) (tomimic
injury-induced inflammatorymilieu) for 24 hr, followed by
quantification of tumor necrosis factor-stimulated gene 6
(Tsg-6), Il-10, Tgf-b1, and Hgf transcripts using real-time
qPCR (Figure 1D). Strikingly, IL-1b stimulation greatly
enhanced the expressionofHgf inMSCs comparedwithun-
stimulated cells. In contrast, Tgf-b1 expression was signifi-
cantly reduced in IL-1b-stimulated MSCs. The steady-state
expression of Tsg-6 was moderately increased, and Il-10
remained unchanged upon IL-1b stimulation. In addition,
ELISA performed on culture supernatants corroborated
the qPCR data and showed a 2.5-fold increase in HGF secre-
tion by IL1b-stimulated MSCs (Figure 1E). These in vitro
data demonstrate that MSCs express high levels of HGF in
an inflamed environment. We also confirmed these find-
ings using human MSCs. Our data showed that human
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bone marrow-derived MSCs constitutively expressed high
levels of HGF, which was significantly upregulated upon
stimulation with recombinant human IL-1b (Figure S1A).
To determine whether in vivo administration of MSCs
leads to high levels of HGF at inflamed injury site, we uti-
lized a well-characterized sterile injury model of mouse
Figure 1. MSCs Secrete High Levels of HGF upon Stimulation with IL-1b
(A) Schematic showing injury model of mouse cornea created by mechanical removal of epithelium and anterior stroma, and effect of
mesenchymal stem cell (MSC) administration on corneal opacity.
(B) Micrographs showing MSC morphology in culture at second passage, and differentiation of MSCs into adipocytes. MSCs were cultured in
adipogenic medium for 2 weeks and stained with oil red O dye; red-colored vacuoles (arrows) were observed within the cytoplasm,
indicating their differentiation into adipocytes. Scale bar, 25 mm.
(C) Phenotypic characterization of in vitro expanded MSCs using flow cytometry confirmed their surface phenotype of CD45–CD34–
SCA1+CD29+CD105+ cells.
(D) MSCs were cultured in medium alone or with IL-1b for 24 hr. mRNA expression of indicated genes in MSCs were analyzed using real-
time PCR.
(E) Protein expression of TGF-b1 and HGF was confirmed in culture supernatants of MSCs cultured in the presence or absence of IL-1b for
24 hr using ELISA. The values of mRNA and protein expression are shown as mean ± SD of three independent experiments.
(F and G) In vitro expanded MSCs were intravenously injected into the C57BL/6 mice 1 hr after corneal injury. Healthy corneas without
injury were used as normal control. Corneas were harvested after 3 days, and (F) mRNA and (G) protein expressions of HGF were measured
using real-time PCR and ELISA, respectively.
The values shown are mean ± SD and each corneal injury group consists of n = 6 mice. *p < 0.003, **p < 0.0001.
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cornea (Basu et al., 2014; Hutcheon et al., 2007). Injury
was induced by mechanical removal of corneal epithelium
and anterior stroma (Figure 1A); 1 hr after injury, MSCs
(5 3 105/0.1 mL/mouse) were intravenously injected in
mice. Using GFP-expressingMSCs (Figure S2), we addition-
ally confirmed that MSCs specifically home to the injured
eye (Lan et al., 2012; Omoto et al., 2014). Normal corneas
without injury and corneas with injury alone (without
MSC administration) served as controls. On day 3 after
injury, corneas were harvested, and qPCR and ELISA were
performed to measure HGF levels. Indeed, injured corneas
from MSC-injected mice showed significantly higher
levels of HGF at both transcript (Figure 1F) and protein
(Figure 1G) levels compared with injured and normal
corneas.
Capacity of MSCs to Restore Corneal Transparency Is
Dependent upon Their HGF Expression
Based on our in vivo data and because previous reports
have ascribed an anti-fibrotic function for HGF (Herrero-
Fresneda et al., 2006), we hypothesized that HGF could
be a putative MSC-expressed factor that could contribute
to the restoration of transparency in injured corneas. We
therefore determined whether altering HGF expression
within MSCs influenced opacity in a sterile injury model
of mouse cornea (Figures 1A and 2A). HGF expression in
MSCs was knocked down using small interfering RNA
(siRNA) (Abed et al., 2015), which led to nearly 80% reduc-
tion of Hgf expression compared with control siRNA (Fig-
ure 2B). MSCs transfected with Hgf siRNA or control siRNA
were pre-stimulated with IL-1b for 6 hr, then intravenously
Figure 2. Restoration of Corneal Transparency Is Dependent upon HGF Expression by MSCs
(A) Schematic of experimental design.
(B) Real-time PCR analysis showing efficacy of Hgf-specific siRNA (siHGF) versus control siRNA (siCON) on downregulation of HGF
expression in mesenchymal stem cells (MSCs). After corneal injury was induced in C57BL/6 mice, MSCs treated with control or Hgf-specific
siRNA were intravenously administered 1 hr post injury and followed for 5 days. At days 1, 3, and 5 post injury, photographs of injured
cornea with or without green fluorescein stain were captured using slit-lamp biomicroscopy. Corneal fluorescein staining was used to
indicate epithelial defects and bright-field micrographs were used to evaluate corneal opacity.
(C and D) Representative bright-field microscopic images of injured cornea (C) were quantitated using Image J software to measure the
corneal opacity scores (D).
(E) Representative biomicroscopic images showing green fluorescein-stained injured cornea.
(F) The fluorescein-stained area was quantitated using ImageJ software. A smaller area of fluorescein staining represents faster repair of
corneal injury.
(G and H) At day 5 post injury, corneas were harvested. Total RNA was isolated from harvested corneas, and real-time PCR was performed to
analyze mRNA expression of (G) a-Sma and (H) Tgf-b1.
The values shown are mean ± SD and each corneal injury group consists of n = 6 mice. *p < 0.02, **p < 0.005.
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Figure 3. HGF Alone Is Sufficient to Inhibit Corneal Opacity and Inflammation
(A and B) A corneal fibroblast cell line (MK/T1) was stimulated with TGF-b1 in the presence or absence of HGF for 24 hr. a-SMA expression
was assessed (A) at mRNA level using real-time PCR and (B) at protein level by immunohistochemistry. The values shown are the mean ± SD
of three independent experiments.
(legend continued on next page)
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administered to the mice 1 hr post injury. Injured corneas
with no MSC administration served as untreated controls.
Slit-lamp biomicroscopy was used to monitor the extent
of corneal opacity and wound healing for 5 days. Corneas
of mice injected with control siRNA-treated MSCs showed
a significant reduction in corneal opacity at days 3 and 5
post injury compared with corneas from Hgf siRNA-treated
MSCs and untreated mice (Figures 2C and 2D). To deter-
mine the extent of wound repair, we used corneal fluores-
cein staining to assess the epithelial defect (Figures 2E
and 2F). A smaller area of fluorescein (green) represents a
faster rate of wound healing. A complete and significantly
more rapid wound repair was seen in mice injected with
control siRNA-treated MSCs compared with corneas from
Hgf siRNA-treated MSCs and untreated control mice. Previ-
ous reports have shown similar effects of wild-type MSCs
on wound repair (Lan et al., 2012; Lee et al., 2014). After
5 days of injury, corneas were harvested to assess expres-
sion levels of a-Sma and Tgf-b1 using qPCR. Data showed
a markedly decreased expression of a-Sma and its inducer
cytokine Tgf-b (Yi et al., 2014) in the corneas of mice
injected with control siRNA-treated MSCs compared with
the corneas of Hgf siRNA-treated MSCs and untreated
mice (Figures 2G and 2H). These data clearly demonstrate
that HGF expression by MSCs is crucial for inhibiting
the expression of opacity-inducing a-SMA and TGF-b,
and restoring corneal transparency in the injured eye.
Topical Administration of HGF Alone Is Sufficient to
Restore Corneal Transparency in Ocular Injury
Finally, the functional and translational relevance of HGF
in restoring corneal transparency was confirmed by inves-
tigating the effect of HGF alone (without MSC administra-
tion) using both in vitro and in vivo model systems. First,
to experimentally address whether HGF can inhibit expres-
sion of a-SMA in corneal fibroblasts, we stimulated a well-
characterized corneal fibroblast cell line (MK/T1) (Gendron
et al., 2001) with TGF-b1 in the absence or presence of re-
combinant mouse HGF for 24 hr. Unstimulated cultures
served as a control. HGF treatment showed a dose-depen-
dent suppression of TGF-b-induced a-Sma expression in
corneal fibroblasts (Figure 3A). Consistent with our data
in mice, we also observed that human recombinant HGF
completely suppressed TGF-b1-induced a-SMA expression
in human corneal fibroblasts (Figure S1B).
We also confirmed the effect of HGF on TGF-b-induced
a-SMA protein expression using immunohistochemistry.
HGF completely suppressed TGF-b-stimulated a-SMA
protein expression in corneal fibroblasts and prevented
their conversion to myofibroblasts (a-SMA+ cells: green)
(Figure 3B), which are the primary cause of corneal opacity
(Jester, 2008; Jiang et al., 2002). Interestingly, HGF treat-
ment (Figures 3A and 3B; media versus HGF) also signifi-
cantly reduced the baseline expression of a-SMA in corneal
fibroblasts, suggesting that HGF alone could be effective in
reversing pre-formed myofibroblasts into a-SMA-negative
fibroblasts. Using this information, we sought to investi-
gate whether in vivo administration of HGF can suppress
corneal opacity. Corneal injury was induced as described
above (Figure 1A), 5 mL of 0.1% recombinant mouse HGF
or mouse serum albumin (control) was applied topically
to the injured eye twice daily for up to 7 days after injury,
and slit-lamp biomicroscopy was used to monitor corneal
opacity (Figure 3C). At day 3 post injury, both groups
showed a significant development of corneal opacity. How-
ever, the corneas of HGF-treated mice exhibited a signifi-
cant reduction in opacity on day 5 and a near complete
restoration of transparency on day 7 compared withmouse
albumin-treated control corneas (Figure 3D). After 7 days
post injury, corneas were harvested to confirm the effect
of HGF on injury-induced opacity at cellular andmolecular
levels. H&E staining of corneal cross-sections revealed
normalization of corneal tissue structures only in HGF-
treated mice (Figure 3E), whereas albumin-treated control
corneas showed a significant increase in tissue thickness
accompanied by infiltration of inflammatory cells (Figures
3E and 3F). Moreover, HGF-treated corneas showed
increased stratification of the epithelial cell layer (Figures
S3A and S3B). Both confocal micrographs of immuno-
stained corneas (Figure 3G) and qPCR (Figure 3H) showed
a significant reduction in the expression of a-SMA
in HGF-treated corneas compared with control corneas.
Moreover, mRNA expression levels of a-SMA-inducer
cytokine Tgf-b1 (Figure 3I), and the inflammatory cyto-
kines Il-1b (Figure 3J) and Tnf-a (Figure 3K) were signifi-
cantly reduced in HGF-treated corneas compared with
(C–K) Corneal injury was induced by mechanical removal of corneal epithelium and anterior stroma in C57BL/6 mice. Thereafter, 5 mL of
0.1% murine recombinant HGF in PBS per eye was applied topically to the injured eye twice a day up to 7 days after injury. A control group
received a similar dosage of mouse serum albumin. At days 1, 3, 5, and 7 post injury, bright-field photographs of injured corneas were
captured to evaluate corneal opacity using slit-lamp biomicroscopy. Representative bright-field images of injured corneas (C) were
quantitated using Image J software to assess corneal opacity scores (D). Corneas were harvested at 7 days post injury. Cross-sections were
stained with H&E to visualize corneal tissue structure and infiltration of inflammatory cells (E), and measure corneal tissue thickness (F).
For immunocytochemistry analysis (G), cross-sections were immunostained with the fibrosis marker a-SMA (green). In addition, harvested
corneas were analyzed for their mRNA expression of (H) a-Sma, (I) Tgf-b1, (J) Il-1b, and (K) Tnf-a using real-time PCR.
The values shown are mean ± SD and each corneal injury group consists of n = 6 mice. *p < 0.01, **p < 0.005. Scale bars, 50 mm.
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albumin-treated corneas. The fact thatHGF-treated corneas
showed high expression of Hgf-R (c-Met) compared with
control corneas (Figure S3C) further supports our finding
that HGF signaling inhibits a-SMA expression. Collec-
tively, these findings indicate that HGF administration
alone is sufficient to restore transparency in corneal injury
by suppressing conversion of corneal fibroblasts into
aSMA+ myofibroblasts and by inhibiting tissue infiltration
of inflammatory cells, which secrete inflammatory cyto-
kines and proteolytic enzymes, leading to degradation
and remodeling of the extracellular matrix (Ljubimov and
Saghizadeh, 2015).
Conventional treatments for ocular injuries involving
corneal scarring vary from topical immunosuppressive ste-
roids to corneal transplantation. However, (1) the increased
risk of infection and delayed wound healing, (2) immune
rejection of the transplant, and (3) shortage of cornea do-
nors remain major limitations to such treatment (Hamil,
2011). Recently, due to their unique immunomodulatory
property, MSCs have been used in experimental and clin-
ical settings to treat a variety of tissue injuries and inflam-
matory diseases (Basu et al., 2014; Lan et al., 2012; Lee
et al., 2014; Uccelli et al., 2008; Wang et al., 2011). Here,
we ascribe a hitherto unknown function of MSCs in
restoring corneal transparency following ocular injury.
We report that MSCs inhibit the expression of opacity-
inducing a-SMA and its inducer TGF-b in the injured
cornea by secreting HGF. Furthermore, we show that
administration of HGF alone can suppress corneal opacity
and inflammation. Given that clinical-grade production
of cell-based therapies is cost prohibitive, our findings
offer the promise of HGF-based modalities for treating
ocular conditions that compromise corneal transparency
and vision.
EXPERIMENTAL PROCEDURES
Animals
Six- to 8-week-old male C57BL/6 wild-type mice (Charles River
Laboratories) were used in these experiments. The protocol was
approved by the Schepens Eye Research Institute Animal Care
and Use Committee, and all animals were treated according to
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research.
Corneal Injury
Mice were anesthetized and a 3-mm superficial keratectomy was
performed as previously described (Basu et al., 2014; Hutcheon
et al., 2007). In brief, under a dissecting microscope the central
area of the cornea was demarcated with a 3-mm trephine and
rotated gently to cut into the stroma. The circular area was traced
with a sharp pair of surgical forceps, and the corneal epithelium
and basement membrane, including the anterior portion of the
stroma, were removed using a hand-held Algerbrush II (Alger
Equipment). Following injury, corneas were flushed with sterile
saline and subsequently covered with Vetropolycin (bacitracin-
neomycin-polymyxin) ophthalmic ointment.
Corneal opacity was determined by taking bright-field images
using a biomicroscope. Corneal wounds were monitored by
placing 1 mL of 2.5% sodium fluorescein (vital staining) on the
ocular surface. After 3 min, the ocular surface was visualized by
slit-lamp biomicroscope under cobalt blue light, and digital pic-
tures of corneal defects were captured. Degree of opacity and area
of injury (fluorescein-stained green color) were calculated using
the NIH ImageJ (version 1.34s) software.
Isolation, Expansion, and Characterization of MSCs
Bone marrow was harvested from femurs of euthanized C57BL/6
mice. MSCs were phenotypically and functionally characterized
as per criteria defined by The International Society for Cellular
Therapy (Dominici et al., 2006), using the previously described
plastic adherence method of MSC cultivation (Lan et al., 2012;
Lee et al., 2014), and bone marrow cells were cultured in murine
MSC-specific MesenCult medium with supplement (STEMCELL
Technologies). Non-adherent cells were removed by changing
medium every 2 days, and at passage 2 the MSCs were harvested
to be used in experiments. Before using MSCs in indicated experi-
ments, cells were characterized phenotypically for the expression
of MSC markers (CD45CD34SCA1+CD29+CD105+) by flow
cytometry and functionally by their in vitro differentiation into
adipocytes using MesenCult adipogenic stimulatory supplements
(STEMCELL). Oil red O (Sigma-Aldrich) staining was used to
confirm the differentiation of MSCs into the adipocytes.
siRNA Transfection
MSCs (1.53 106 cells) were plated in a 75-cm2 flask and incubated
for 18–24 hr to reach to 60%–70% confluency. The cells were then
washed and transfected with 4.8 mg of Hgf-specific or non-specific
control siRNA duplex using transfection reagent in siRNA transfec-
tionmedium according to the protocol suggested by the manufac-
turer (Santa Cruz Biotechnology). After overnight incubation,
transfection medium was replaced with normal MSC growth cul-
ture medium and cells were cultured for an additional 2 days.
Knockdown efficiency of siRNA was validated by real-time PCR
using Hgf-specific primers after 2 and 5 days of transfection.
MSC or HGF Administration
In vitro expanded wild-type or Hgf-silenced MSCs were pre-stimu-
lated with IL-1b for 6 hr, and 5 3 105 MSCs in 100 mL of normal
saline per mouse were injected to mice 1 hr after corneal injury.
Mice were placed in a restraining tube without anesthesia and
the tail cleaned with 70% ethanol. The tail was pulled gently and
cells in 100 mL of PBS were injected into the tail vein. Five microli-
ters of 0.1% murine recombinant HGF protein (R&D Systems) or
mouse serum albumin (Sigma-Aldrich) was applied topically to
the injured eye twice daily for up to 7 days after injury.
In Vitro MK/T1 Cell Stimulation
The mouse corneal fibroblast cell line MK/T1 (Gendron et al.,
2001) was seeded at 1 3 105 cells per well in 24-well plates and
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cultured in medium alone or stimulated with 100 ng/mL murine
recombinant TGF-b1 (R&D Systems) in the presence or absence
of murine recombinant HGF (R&D Systems) at indicated doses
for 24 hr. Cells were then used for evaluation of a-Sma expression
by real-time PCR and immunohistochemistry.
RNA Isolation and Real-Time qPCR
Total RNA was isolated using the RNeasy Micro Kit (Qiagen).
Isolated RNA was reverse transcribed into cDNA using oligo(dT)
primer and SuperScript III (Invitrogen). Real-time qPCR was
then performed using Taqman Universal PCR Mastermix and
pre-formulated Taqman primers for murine glyceraldehyde-3-
phosphate dehydrogenase (Gapdh), Hgf, Il-10, Tsg6, Il-1b, Tgf-b1,
Tnf-a, and a-Sma (Life Technologies). The results were analyzed
by the comparative threshold cycle method and normalized to
Gapdh as an internal control.
Immunohistochemistry and Histology
Cryosections of the whole eyeball and fibroblast culture on
8-chamber slides were fixed in acetone and blocked with 2%
BSA and anti-FcR antibodies (catalog #14-0161-86, Affymetrix
eBioscience). The sections were immunostained with Alexa Fluor
488-conjugated anti-a-SMA or isotype-matched control antibodies
(#53-6496-80, Affymetrix) overnight at 4C. Slides were then
mounted using Vector Shield mounting medium (Vector Labora-
tories) and examined under a confocalmicroscope. For histological
evaluation, corneal sections were stained with H&E and examined
using bright-field microscopy.
Flow Cytometry
A single-cell suspension of MSCs was prepared and stained with
fluorochrome-conjugated monoclonal antibodies and appropriate
isotype controls. Antibodies (Biolegend) against CD45 (catalog
#103133), CD34 (#119310), SCA-1 (#108105), CD29 (#102207),
and CD105 (#120407) were used for the phenotypic characteriza-
tion of MSCs. Stained cells were analyzed on an LSR-II flow cytom-
eter (BD Biosciences).
ELISA
Levels of TGF-b1 and HGF in supernatants of MSC cultures or
corneal lysates were analyzed using commercially availablemurine
ELISA kits (R&D Systems) as per the manufacturer’s instructions.
Statistical Analysis
Mann-Whitney U tests or Student’s t tests were performed to deter-
mine significance, which was set at p < 0.05. Results are presented
as the mean ± SD of three independent experiments. In vivo eval-
uations and quantification of images of corneal injury and opacity
were performed in a masked fashion. Samples sizes were estimated
on the basis of previous experimental studies on corneal injury and
inflammation (Lan et al., 2012; Basu et al., 2014).
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